The S&P BSE Sensex jumped 53.12 points or 0.07% to 74,036.30 and the Nifty 50 index rose 24.50 points or 0.06% to 23,224.40 at 14:30 IST, showing signs of recovery from earlier session lows. According to Business Standard, the broader market underperformed with the BSE 150 MidCap Index falling 0.62% and the BSE 250 SmallCap Index shedding 0.55%. Market breadth remained weak with 1,303 shares rising and 2,792 shares falling on the BSE, while 191 shares remained unchanged. The Nifty Pharma index advanced 1.03% to 24,410.10, extending gains for the second consecutive trading session with a 1.1% rise over two sessions. In the commodities market, Brent crude for August 2026 settlement declined $1.30 or 1.40% to $91.80 a barrel.
Wockhardt emerged as the top performer with 5.13% gains, followed by Gland Pharma at 3.47%, Torrent Pharmaceuticals at 3.05%, JB Chemicals & Pharmaceuticals at 2.91%, and Ajanta Pharma at 2.23%. As reported by Business Standard, other notable gainers included Lupin (up 1.4%), Aurobindo Pharma (up 1.2%), Biocon (up 1.07%), Sun Pharmaceutical Industries (up 0.81%), and Mankind Pharma (up 0.74%). The previous session saw Alkem Laboratories leading with 2.54% gains at ₹5,385 and Mankind Pharma at 1.75% at ₹2,377. However, some pharmaceutical stocks faced pressure, with Wockhardt emerging as the biggest loser, falling over 2.3%, while Lupin, Cipla, Piramal Pharma, and Laurus Labs also traded lower with declines of 0.3% to 0.8%.
According to The Economic Times, Indian pharma stocks have emerged as one of the market's best-performing defensive bets, with the Nifty Pharma index gaining about 6% year-to-date, sharply outperforming broader markets. In comparison, the Nifty is down 11%, Nifty IT has fallen 24%, while both Nifty Bank and Nifty Auto have declined around 8% over the same period. Several pharma stocks have delivered exceptional returns despite challenging market conditions, with Gland Pharma surging nearly 33% this year, followed by Wockhardt at 30%, Laurus Labs at 29%, Aurobindo Pharma at 22%, JB Chemicals at 21%, Zydus Life at 21% and Torrent Pharma at 16%. The outperformance has come at a time when investors have been grappling with geopolitical tensions, tariff uncertainties, slowing corporate earnings growth and concerns over global economic momentum.
The brokerage noted that cumulative domestic growth for its pharma coverage universe stood at 14% year-on-year during the quarter, with companies such as Dr Reddy's, Torrent Pharma, Sun Pharma and Cipla reporting some of the strongest growth rates. As reported by The Economic Times, unlike export-oriented sectors that remain vulnerable to tariff risks and global demand fluctuations, Indian pharma companies derive a significant share of revenues from domestic healthcare spending, which has remained robust. This domestic strength provides stability during challenging global conditions, with the sector benefiting from consistent healthcare demand regardless of economic volatility.
The brokerage believes healthcare will benefit from several structural trends over the next decade, including ageing populations, rising healthcare spending, obesity treatments, preventive medicine, vaccines, digital healthcare and artificial intelligence-led innovation. According to The Economic Times, Bernstein estimates that incremental innovation could expand the size of India's biopharma industry to nearly $195 billion over the next decade, almost four times current levels. The brokerage also expects AI adoption to improve operational efficiency across the sector, potentially adding three to four percentage points to profit margins over time. Additionally, Elara Securities noted that the move is sentimentally positive for Indian contract development and manufacturing companies because it could encourage global pharmaceutical firms to diversify supply chains away from China, with Indian players such as Divi's Laboratories, Laurus Labs, Syngene and other CDMO companies among the beneficiaries of this supply-chain diversification theme.
